Development of a novel peptide-based therapeutic compound against CML by targeting the PH domain of p210 BCR-ABL

Aoi Ikegami

[1P-302（2T14a-02）] Development of a novel peptide-based therapeutic compound against CML by targeting the PH domain of p210 BCR-ABL

^〇Aoi Ikegami¹, Miho Takahashi¹, Masaya Tyoda¹, Kentaro Shimasaki², Norihito Shibata³, Mikihiko Naito⁴, Kiyotaka Nishikawa¹ (1.Molecular Life Sciences Laboratory, Faculty of Life and Medical Sciences, Doshisha University, 2.Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, 3.Division of Biochemistry Section2, National Institute of Health Sciences, 4.Laboratory of Targeted Protein Degradation, Graduate School of Pharmaceutical Sciences, The University of Tokyo)

キーテクノロジー：多価型ペプチドライブラリー法

CML、PHドメイン、ミトコンドリア、カルジオリピン、マイトファジー

ctug2007@mail4.doshisha.ac.jp

Contents of this site has moved to the member page of The Japanese Biochemical Society: https://member.jbsoc.or.jp/mypage/
You can access the abstracts without credentials by accessing them via the member page.

You need the membership number and password to access the member page. Please contact the journal office for any inquiries.

Journal Office Contact Information:
E-mail:jbs-ho@jbsoc.or.jp
Tel:03(3815)1913 Fax:03(3815)1934

The 95th Annual Meeting of the Japanese Biochemical Society

[1P-302（2T14a-02）] Development of a novel peptide-based therapeutic compound against CML by targeting the PH domain of p210 BCR-ABL

Password